The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis.

about

The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis.

Item

http://www.wikidata.org/entity/Q36963349

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The Birmingham Vasculitis Acti ...... nts with Giant Cell Arteritis.

@en

type

Item

label

The Birmingham Vasculitis Acti ...... nts with Giant Cell Arteritis.

@en

prefLabel

The Birmingham Vasculitis Acti ...... nts with Giant Cell Arteritis.

@en

P1476

The Birmingham Vasculitis Acti ...... nts with Giant Cell Arteritis.

@en

P2093

Carol A Langford

http://www.w3.org/2001/XMLSchema#string

Carol A McAlear

http://www.w3.org/2001/XMLSchema#string

Curry L Koening

http://www.w3.org/2001/XMLSchema#string

David Cuthbertson

http://www.w3.org/2001/XMLSchema#string

Eric L Matteson

http://www.w3.org/2001/XMLSchema#string

Gary S Hoffman

http://www.w3.org/2001/XMLSchema#string

Kathleen McKinnon-Maksimowicz

http://www.w3.org/2001/XMLSchema#string

Kenneth J Warrington

http://www.w3.org/2001/XMLSchema#string

Nader A Khalidi

http://www.w3.org/2001/XMLSchema#string

Paul A Monach

http://www.w3.org/2001/XMLSchema#string

P2860

Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.

Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.

Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.

The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis

Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study.

Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients

The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.

Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease.

P304

1078-1084

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3899/JRHEUM.151063

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Philip Seo

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27036388

http://www.w3.org/2001/XMLSchema#string

P932

4891218

http://www.w3.org/2001/XMLSchema#string